MSB Trading - 2019, page-48

New FDA drug approvals hit their stride in 2018...Cancer drugs came out tops with 16 approvals ..The number of rare diseases approvals almost matched that of the cancer approvals ..So what was behind the boost of approvals in 2018 ,analyst Jon Miller says it's hard to say it's a trend ,that said ,the FDA over the last couple of years has been increasingly concillary ,and I don't mean that they are letting bad drugs thru , but they have been putting less resistance to certain things ..The FDA is becoming more willing especially in rare disease and restricted patient population with high met needs on what might have counted as thin evidence 5-8 years ago ......